Clinical Testing for Precision Medicine in Drug Development
Rohith, Editorial Team, Pharma Focus Europe
Precision medicine, through clinical testing, is changing how drugs are developed, by customising treatments to genetic, molecular, as well as patient-specific variables. Biomarkers, adaptive trial designs and digital tools allow the use of a targeted approach, whilst some issues are limited population size, cost and regulation. This article discusses novelty, case studies and future trends that are influencing personalised healthcare.
The model of drug development has traditionally been based on the one-size fits all concept whereby therapeutic measures are tested and approved on the basis of their overall effect on large groups. Although this has been a source of numerous medical developments, it tends to overlook the biological differences that patients can be having. Precision medicine is designed to transform this paradigm by adopting treatments that are specific to the characteristics of people, including genetics, environment, and lifestyle.
One of the key factors on which the practice of precision medicine is grounded is clinical testing. In contrast to the old-fashion method of drug testing, when it is conducted with general groups of patients, the process of clinical testing based on precision medicine is arranged on the principle of patient stratification by biomarkers and new diagnostic methods. This guarantees treatments are targeted to the individuals who are most likely to improve and that the rest are not subjected to wasteful side effects.
Precision medicine has already started changing the strategy in oncology, rare diseases, and immunology in the drug development pipeline. The core of this change consists in the fact that the methods of clinical testing are becoming more adaptive, data-based, and patient-centric.
The Evolution of Clinical Testing in Drug Development
Conventional clinical testing was based on a strict linear approach with Phase I to determine safety, Phase II to investigate efficacy, and Phase III to determine effectiveness in large groups. This model was resource-intensive and overly complex to the precision medicine complexity, albeit organised.
The emergence of the biomarker-driven development of drugs has necessitated a different mode of thinking. Precision trials, instead of using thousands of patients to establish a general efficacy, tend to use highly stratified groups of fewer patients in studies based on genetic or molecular markers of eligibility. This method would make the process more efficient, but a new issue emerges as well, including the problem of recruiting people and the necessity to perform more sophisticated diagnostics to prove that patients are suitable.
A good example was provided in oncology. One of the first examples of the biomarker-driven testing is the approval of trastuzumab in HER2-positive breast cancer in the late 1990s. Since, EGFR inhibitors against lung cancer and BRAF against melanoma have demonstrated how stratified clinical trials can change the outcomes.
Precision Medicine: Definition and Scope
This framework depends on clinical testing using biomarkers, molecular profiling and diagnostic tools that can be used to classify the patients according to how they are expected to respond to a treatment.
Key components include:
• Biomarkers: Genetic mutations, levels of a protein or any other biological indicators predicting the response to treatment.
• Companion diagnostics: Tests that are created together with the treatment to determine qualified patients.
• Omics technologies: Genomics, proteomics and transcriptomics to map disease processes on a small scale.
Precision medicine subgroups patients of similar disease into subgroups on the contrary to traditional medicine, where the homogeneous group is treated as such. This redefines the development of therapies as well as the structure and evaluation of clinical trials.
Innovations in Clinical Testing for Precision Medicine
Adaptive Trial Designs
Adaptive trial designs enable any changes on the basis of interim findings without interfering with the scientific integrity of the study. These are adjustments in dosage, patient stratification and even trial endpoints. Adaptive trials are of particular use in precision medicine since the groups of patients considered are smaller and more diverse.
Basket and Umbrella Trials
• Basket trials are used to test a drug in more than one disease that has the same biomarker. Indicatively, a NTRK gene fusions treatment could be investigated in different cancers.
• Umbrella trials are used to assess more than one therapy in a disease type using varied biomarkers. As an example, trials of targeted EGFR, ALK, or ROS1 treatment can be conducted concurrently in lung cancer.
Both designs indicate the manner in which clinical testing can be adjusted to the genetic and molecular complexity of disease.
Integration of Next-Generation Sequencing (NGS)
With NGS technologies, severe and affordable sequencing of complete genomes or targeted panels is achievable. NGS is also applied in clinical testing to determine patient eligibility, observe treatment response, and identify resistance mechanisms.
Digital and Remote Monitoring
Wearable devices and mobile apps increasingly enable real-time patient monitoring during trials. Such instruments facilitate decentralised clinical testing, thus facilitating the ease of recruiting a variety of populations as well as gathering continuous data out of conventional hospital environments.
Data, Digital Tools, and Biomarkers in Clinical Testing
AI and Machine Learning
AI is changing the methods of patient recognition and trial result analysis in clinical testing.
Real-World Data and Real-World Evidence
Regulators are accepting RWE with clinical trial data more and more often. Electronic health records, wearables, and patient registries produce RWD that may be used to supplement trial findings, particularly in rare diseases, where the number of patients is small.
Biomarker Validation
The trials in precision medicine depend on biomarkers. Their reliability and reproducibility have to be validated which is a paramount task. The regulatory agencies tend to insist on evidence that the biomarkers employed to select the patients are strong and with clinical significance.
Challenges in Implementing Precision Medicine Clinical Trials
Small Patient Populations
Precision medicine by definition aims at small subsets of patients. Although this enhances the chance of success in therapy, recruitment becomes difficult and the trial schedules become extended.
Cost and Complexity
Genetic sequencing, companion diagnostics and biomarker assays elevate the cost of a trial. Further, it is logistically challenging to make diagnostic platforms globally available.
Regulatory Hurdles
Regulators should consider therapeutics and diagnostics as a single entity, which develops multifaceted review mechanisms. The harmonisation of agencies like the FDA and EMA is not complete yet.
Ethical Considerations
Genetic testing usually comes with the field of precision medicine, which impairs privacy, informed consent, and fair access. Ethical models need to be adjusted to guarantee trust and data protection of the patients.
Case Studies: Oncology, Rare Diseases, and Genetic Therapies
Oncology
Oncology has been the most affected by precision medicine. For example:
• Imatinib chronic myeloid leukaemia, a BCR-ABL fusion.
• Pembrolizumab in MSI-high malignancies, which is endorsed in various tumours.
• CAR-T cell therapies in which immunity cells of the patient are modified to be specific to cancer targets.
These achievements demonstrate that biomarker-based testing can speed up approvals and achieve significant results.
Rare Diseases
In cases like spinal muscular atrophy (SMA), treatments such as nusinersen have come forth after genetic markers have been discovered. Small patient pools could be translated into treatments quickly through precision clinical testing of findings.
Genetic Therapies
New gene-editing methods such as the CRISPR-based therapy are undergoing clinical trial. These clinical trials are characterised by an extremely stratified patient population, usually a single-gene disease like sickle cell. The pitfalls in this area point to the hope and difficulty of precision medicine clinical testing.
Regulatory and Ethical Considerations
Regulatory Approaches
The FDA and the EMA have both presented frameworks to support biomarker-driven and adaptive trials. To illustrate, the FDA issued a recommendation on companion diagnostics, as well as the adaptive pathways program by EMA, is a sign of increased regulatory permissiveness. However, requirements for biomarker validation and diagnostic co-approval remain demanding.
Ethics in Genetic Testing
Given genetic information the informed consent is more complicated. Patients also need to know the potential implication of the use of their information in the trial besides understanding how it is going to be used.
Equity of Access
Precision medicine also threatens to increase the gap between high-income and low-income areas in case innovative diagnostics and treatments are confined there. Ethical models pay an increasing stress on accessibility and affordability throughout the rest of the world.
Future Outlook
Decentralised and Hybrid Trials
Decentralised clinical trials (DCTs) are a hybrid of in-person and remote involvement, enabled by wearables, telemedicine, and digital platform. This model makes the patients more convenient and recruiting becomes more diverse.
Digital Twins
Digital twin technology, which involves developing a virtual copy of a patient, is a form of simulation of responses to treatments. Digital twins can also be used to complement clinical testing in the future by yielding predictions prior to experimentation.
Integration of Multi-Omics
Outside genomics, precision medicine is also beginning to use proteomics, metabolomics, and microbiomics. Clinical testing of multi-omics will enhance the knowledge of the disease pathway and increase personalised treatment therapies.
Broader Applications
Although oncology and rare diseases are in the lead, precision medicine is spread to cardiology, neurology, and infectious diseases. To perform clinical testing in these domains, there will be a need to open up new ways of stratifying patients using complicated biomarker trends.
Conclusion
Precision medicine in clinical testing is ceasing to be a niche pursuit in drug development; it is emerging as being a staple of contemporary therapeutics. Clinical trials are transforming with the complexity of human biology by combining biomarkers, adaptive designs and digital technologies.
Yet challenges remain. The challenge of small patient piles, escalating cost, and complex regulations needs to be overcome in case precision medicine can live up to its promise all over the world. The regulators, industry, academia, and the patient communities will have to cooperate to achieve success.
The future is in a patient-centric model where the therapies are to be created not to the typical patient, but rather to the right patient at the right time. Clinical testing will continue to play the decisive role that links scientific discovery with therapeutic intervention to create a healthcare environment that is genuinely personalised.
Author Bio
Rohith, Editorial Team at Pharma Focus Europe, leverages his extensive background in pharmaceutical communication to craft insightful and accessible content. With a passion for translating complex pharmaceutical concepts, Rohith contributes to the team's mission of delivering up-to-date and impactful information to the global Pharmaceutical community.
